NCT04272463 (ANANKE) is a clinical trial of No intervention in Severe Asthma, sponsored by AstraZeneca.

Who is sponsoring NCT04272463?

NCT04272463 is sponsored by AstraZeneca.

What drugs are being tested in NCT04272463?

Interventions in NCT04272463: No intervention.

What condition does NCT04272463 study?

NCT04272463 studies Severe Asthma.

Is NCT04272463 still recruiting?

NCT04272463 is currently completed. Last updated 31 August 2023.

Last reviewed 2023-08-31 · How we verify

NCT04272463: ANANKE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ChAracterisation of ItaliaN Severe Uncontrolled Asthmatic patieNts Key Features When Receiving Benralizumab

Completed Last updated 31 August 2023

What this trial tests

trial testing No intervention in Severe Asthma in 217 participants. Completed in 15 July 2020.

Timeline

13 March 2020

Primary endpoint
15 July 2020

15 July 2020

Quick facts

Lead sponsor	AstraZeneca
Status	Completed
Study type	OBSERVATIONAL
Enrollment	217
Start date	13 March 2020
Primary completion	15 July 2020
Estimated completion	15 July 2020
Sites	18 locations across Italy

Drugs / interventions tested

No intervention

Conditions studied

Severe Asthma — all drugs for Severe Asthma →

Sponsor

AstraZeneca — full company profile →

Who can join

Eligibility, any sex, with Severe Asthma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an observational, Italian multi-center, retrospective cohort study with enrollment visit on patients suffering from severe eosinophilic asthma who started benralizumab in the Sampling Program or as per normal clinical practice in Italy.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study.
Menzella F, Bargagli E, Aliani M, Bracciale P, et al · · 2022 · cited 36× · PMID 35183167 · DOI 10.1186/s12931-022-01952-8
Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study.
Vultaggio A, Aliani M, Altieri E, Bracciale P, et al · · 2023 · cited 31× · PMID 37210543 · DOI 10.1186/s12931-023-02439-w
Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis.
D'Amato M, Menzella F, Altieri E, Bargagli E, et al · · 2022 · cited 16× · PMID 35769575 · DOI 10.3389/falgy.2022.881218
Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis.
Caruso C, Cameli P, Altieri E, Aliani M, et al · · 2022 · cited 13× · PMID 36117962 · DOI 10.3389/fmed.2022.950883
Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study.
Cameli P, Aliani M, Altieri E, Bracciale P, et al · · 2024 · cited 4× · PMID 38562251 · DOI 10.2147/jaa.s438981
Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study.
Senna G, Aliani M, Altieri E, Bracciale P, et al · · 2022 · cited 4× · PMID 36387835 · DOI 10.2147/jaa.s383012
Benralizumab and the integrated management of co-morbid severe eosinophilic asthma with chronic rhinosinusitis with nasal polyps.
Mullol J, D'Amato M, de Corso E, Han JK, et al · · 2025 · cited 2× · PMID 40200389 · DOI 10.1002/clt2.70051
Durability of benralizumab effectiveness in severe eosinophilic asthma patients with and without chronic rhinosinusitis with nasal polyps: a post hoc analysis from the ANANKE study.
Brussino L, Aliani M, Altieri E, Bracciale P, et al · · 2025 · cited 2× · PMID 40181809 · DOI 10.3389/falgy.2025.1501196

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

NCT06643052 — Cahnge in Management of Suspected Early Onset Neonetal Sepsis After Assimilation of Early Onset Sepsis Calculator · not yet recruiting
NCT07540611 — Gonadotropin Therapy in Idiopathic Hypogonadal Non-Obstructive · NA · not yet recruiting
NCT07291778 — Doppler Evaluation for Congestive Acute Kidney Injury in Critical Illness · NA · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT07515365 — Colitis Patterns in Patients With Lower GI Symptoms · not yet recruiting

Other recruiting trials for Severe Asthma

Currently open trials in the same condition.

NCT07363642 — Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab · Phase 3 · recruiting
NCT07328035 — Remission in Adults With Severe Asthma in Thailand · recruiting
NCT07530770 — Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis · recruiting
NCT06903780 — Experience of Biologic Treatments for Severe Asthma: a Survey · recruiting
NCT06681545 — Exploring the Lived Experience of Young Adults With Severe Asthma · recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04272463 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 31 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04272463.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing